HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Horlicks Brings Unilever 'Transformative' Nutritional Deal, Market Challenges

This article was originally published in The Rose Sheet

Executive Summary

Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.

You may also be interested in...



GSK Rejects £50bn Bid For Consumer Healthcare From Unilever

GSK says London-based Unilever's £50bn bid for Consumer Healthcare fundamentally undervalues a business which generated sales close to £10bn last year and is expected to grow 4-6% over the medium term. The rejection has not dissuaded Unilever, however, with the company intent on stepping up its presence in the health, beauty and hygiene categories.

GSK Generates Additional £0.5bn From India Biz Sale

GSK Consumer Healthcare's sale of its Indian business has generated £0.5bn more than expected thanks to the increased value of its holding in Hindustan Unilever.

GSK Begins ‘New Chapter’ in India As It Offloads Nutrition Brands

GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel